Cell Death & Disease-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2247139, encodeId=be09224e13960, content=2024.8.14 submission 2024.8.14-8.26 editor assignment 2024.8.27 with editor 2024.9.26 接到一审回来的邮件（两个审稿人，给了两个月的时间返修） 2024.11.13 返修回去（一直是under consideration,有zip文件） 2024.12.3 dicision made 2024.12.6 小修邮件 2024.12.7 返修回去 2024.12.9 dicision made 2024.12.17 Accept in Priciple 然后提交了一个最终版本，到现在还没消息，一直是under consideration;已经20天了，有没有大神能告诉我多久能收到Proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8215640014, createdName=ms1000002147178519, createdTime=Wed Jan 08 16:00:35 CST 2025, time=2025-01-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2227948, encodeId=f420222e94880, content=偏重的研究方向：肿瘤;机制研究 经验分享：速度蛮快从大cdd转来第1天分配编辑当天即送审两周后审完给修花一个月补了实验修回修回第二天decision made 一周后原则性接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf531737941, createdName=yuig, createdTime=Fri Sep 27 08:10:40 CST 2024, time=2024-09-27, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2243526, encodeId=baaa2243526b2, content=一审128天了，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d976564110, createdName=ms1000001793243476, createdTime=Thu Dec 19 13:40:02 CST 2024, time=2024-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2233713, encodeId=68222233e13ab, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：大家好，想请问下大家，review square在哪可以看呀，目前一审修回后一周，想看一下二审是否有审稿人接受审稿。另外想请问大佬们，一审修回的几个图有点问题（不影响结果），后续可以更换图吗？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86504809827, createdName=473565137, createdTime=Mon Oct 28 17:10:32 CST 2024, time=2024-10-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2208022, encodeId=4385220802237, content=二审后made decision 已经两周了有这个情况的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d548736549, createdName=ms4000000513308957, createdTime=Mon Jun 03 10:20:30 CST 2024, time=2024-06-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2232987, encodeId=45d3223298e3b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学 经验分享：3月底投稿 4月26修回意见，期间状态一直是under consideration， 5.29上传修回稿 8.14接受。 总的来说还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822126, createdTime=Thu Oct 24 23:44:21 CST 2024, time=2024-10-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2227972, encodeId=34ed222e972bd, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌;增殖 经验分享：2nd 08 Submission 2nd 08 Under Consideration 24th 09 Decision Made 26th 09 收到邮件【I regret that I am unable to accept the manuscript for publication】 审稿人1：This paper does not provide any new insight. 审稿人2：I find this study suitable for publication. 综上所述，耗时近2个月，最终被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoFGKyniaLjSy7KwQPyDticyTh8W1P6Ptj682WnB3goasd1PiaaBDpLrRgCSP813Vug94Q5Ge9PNHZsw/132, createdBy=dafd2460608, createdName=xie17, createdTime=Fri Sep 27 11:02:36 CST 2024, time=2024-09-27, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海)]

2025-01-08 ms1000002147178519 来自安徽省

2024.8.14 submission
2024.8.14-8.26 editor assignment
2024.8.27 with editor
2024.9.26 接到一审回来的邮件（两个审稿人，给了两个月的时间返修）
2024.11.13 返修回去（一直是under consideration,有zip文件）
2024.12.3 dicision made
2024.12.6 小修邮件
2024.12.7 返修回去
2024.12.9 dicision made
2024.12.17 Accept in Priciple
然后提交了一个最终版本，到现在还没消息，一直是under consideration;已经20天了，有没有大神能告诉我多久能收到Proof呀？

3 0

[GetPortalCommentsPageByObjectIdResponse(id=2247139, encodeId=be09224e13960, content=2024.8.14 submission 2024.8.14-8.26 editor assignment 2024.8.27 with editor 2024.9.26 接到一审回来的邮件（两个审稿人，给了两个月的时间返修） 2024.11.13 返修回去（一直是under consideration,有zip文件） 2024.12.3 dicision made 2024.12.6 小修邮件 2024.12.7 返修回去 2024.12.9 dicision made 2024.12.17 Accept in Priciple 然后提交了一个最终版本，到现在还没消息，一直是under consideration;已经20天了，有没有大神能告诉我多久能收到Proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8215640014, createdName=ms1000002147178519, createdTime=Wed Jan 08 16:00:35 CST 2025, time=2025-01-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2227948, encodeId=f420222e94880, content=偏重的研究方向：肿瘤;机制研究 经验分享：速度蛮快从大cdd转来第1天分配编辑当天即送审两周后审完给修花一个月补了实验修回修回第二天decision made 一周后原则性接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf531737941, createdName=yuig, createdTime=Fri Sep 27 08:10:40 CST 2024, time=2024-09-27, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2243526, encodeId=baaa2243526b2, content=一审128天了，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d976564110, createdName=ms1000001793243476, createdTime=Thu Dec 19 13:40:02 CST 2024, time=2024-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2233713, encodeId=68222233e13ab, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：大家好，想请问下大家，review square在哪可以看呀，目前一审修回后一周，想看一下二审是否有审稿人接受审稿。另外想请问大佬们，一审修回的几个图有点问题（不影响结果），后续可以更换图吗？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86504809827, createdName=473565137, createdTime=Mon Oct 28 17:10:32 CST 2024, time=2024-10-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2208022, encodeId=4385220802237, content=二审后made decision 已经两周了有这个情况的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d548736549, createdName=ms4000000513308957, createdTime=Mon Jun 03 10:20:30 CST 2024, time=2024-06-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2232987, encodeId=45d3223298e3b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学 经验分享：3月底投稿 4月26修回意见，期间状态一直是under consideration， 5.29上传修回稿 8.14接受。 总的来说还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822126, createdTime=Thu Oct 24 23:44:21 CST 2024, time=2024-10-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2227972, encodeId=34ed222e972bd, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌;增殖 经验分享：2nd 08 Submission 2nd 08 Under Consideration 24th 09 Decision Made 26th 09 收到邮件【I regret that I am unable to accept the manuscript for publication】 审稿人1：This paper does not provide any new insight. 审稿人2：I find this study suitable for publication. 综上所述，耗时近2个月，最终被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoFGKyniaLjSy7KwQPyDticyTh8W1P6Ptj682WnB3goasd1PiaaBDpLrRgCSP813Vug94Q5Ge9PNHZsw/132, createdBy=dafd2460608, createdName=xie17, createdTime=Fri Sep 27 11:02:36 CST 2024, time=2024-09-27, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海)]

2024-07-19 Judy Bright 来自广东省

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肺癌;肿瘤生物学
经验分享：今天刚刚接收一篇，分享一下投稿经历：

第一阶段：
Submission ---- 25th Jan 24
Under Consideration ---- 26th Jan 24
Decision Made ---- 9th Apr 24
收到一审意见 ---- 15th Apr 24

第二阶段：
Submission ---- 20th Jun 24
Under Consideration ---- 20th Jun 24
Decision Made ---- 15th Jul 24
Accepted in Principle ---- 19th Jul 24

628 35

展开35条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247139, encodeId=be09224e13960, content=2024.8.14 submission 2024.8.14-8.26 editor assignment 2024.8.27 with editor 2024.9.26 接到一审回来的邮件（两个审稿人，给了两个月的时间返修） 2024.11.13 返修回去（一直是under consideration,有zip文件） 2024.12.3 dicision made 2024.12.6 小修邮件 2024.12.7 返修回去 2024.12.9 dicision made 2024.12.17 Accept in Priciple 然后提交了一个最终版本，到现在还没消息，一直是under consideration;已经20天了，有没有大神能告诉我多久能收到Proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8215640014, createdName=ms1000002147178519, createdTime=Wed Jan 08 16:00:35 CST 2025, time=2025-01-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2227948, encodeId=f420222e94880, content=偏重的研究方向：肿瘤;机制研究 经验分享：速度蛮快从大cdd转来第1天分配编辑当天即送审两周后审完给修花一个月补了实验修回修回第二天decision made 一周后原则性接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf531737941, createdName=yuig, createdTime=Fri Sep 27 08:10:40 CST 2024, time=2024-09-27, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2243526, encodeId=baaa2243526b2, content=一审128天了，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d976564110, createdName=ms1000001793243476, createdTime=Thu Dec 19 13:40:02 CST 2024, time=2024-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2233713, encodeId=68222233e13ab, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：大家好，想请问下大家，review square在哪可以看呀，目前一审修回后一周，想看一下二审是否有审稿人接受审稿。另外想请问大佬们，一审修回的几个图有点问题（不影响结果），后续可以更换图吗？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86504809827, createdName=473565137, createdTime=Mon Oct 28 17:10:32 CST 2024, time=2024-10-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2208022, encodeId=4385220802237, content=二审后made decision 已经两周了有这个情况的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d548736549, createdName=ms4000000513308957, createdTime=Mon Jun 03 10:20:30 CST 2024, time=2024-06-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2232987, encodeId=45d3223298e3b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学 经验分享：3月底投稿 4月26修回意见，期间状态一直是under consideration， 5.29上传修回稿 8.14接受。 总的来说还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822126, createdTime=Thu Oct 24 23:44:21 CST 2024, time=2024-10-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2227972, encodeId=34ed222e972bd, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌;增殖 经验分享：2nd 08 Submission 2nd 08 Under Consideration 24th 09 Decision Made 26th 09 收到邮件【I regret that I am unable to accept the manuscript for publication】 审稿人1：This paper does not provide any new insight. 审稿人2：I find this study suitable for publication. 综上所述，耗时近2个月，最终被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoFGKyniaLjSy7KwQPyDticyTh8W1P6Ptj682WnB3goasd1PiaaBDpLrRgCSP813Vug94Q5Ge9PNHZsw/132, createdBy=dafd2460608, createdName=xie17, createdTime=Fri Sep 27 11:02:36 CST 2024, time=2024-09-27, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海)]

2024-09-27 yuig 来自福建省

偏重的研究方向：肿瘤;机制研究
经验分享：速度蛮快从大cdd转来第1天分配编辑当天即送审两周后审完给修花一个月补了实验修回修回第二天decision made 一周后原则性接收

52 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247139, encodeId=be09224e13960, content=2024.8.14 submission 2024.8.14-8.26 editor assignment 2024.8.27 with editor 2024.9.26 接到一审回来的邮件（两个审稿人，给了两个月的时间返修） 2024.11.13 返修回去（一直是under consideration,有zip文件） 2024.12.3 dicision made 2024.12.6 小修邮件 2024.12.7 返修回去 2024.12.9 dicision made 2024.12.17 Accept in Priciple 然后提交了一个最终版本，到现在还没消息，一直是under consideration;已经20天了，有没有大神能告诉我多久能收到Proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8215640014, createdName=ms1000002147178519, createdTime=Wed Jan 08 16:00:35 CST 2025, time=2025-01-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2227948, encodeId=f420222e94880, content=偏重的研究方向：肿瘤;机制研究 经验分享：速度蛮快从大cdd转来第1天分配编辑当天即送审两周后审完给修花一个月补了实验修回修回第二天decision made 一周后原则性接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf531737941, createdName=yuig, createdTime=Fri Sep 27 08:10:40 CST 2024, time=2024-09-27, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2243526, encodeId=baaa2243526b2, content=一审128天了，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d976564110, createdName=ms1000001793243476, createdTime=Thu Dec 19 13:40:02 CST 2024, time=2024-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2233713, encodeId=68222233e13ab, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：大家好，想请问下大家，review square在哪可以看呀，目前一审修回后一周，想看一下二审是否有审稿人接受审稿。另外想请问大佬们，一审修回的几个图有点问题（不影响结果），后续可以更换图吗？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86504809827, createdName=473565137, createdTime=Mon Oct 28 17:10:32 CST 2024, time=2024-10-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2208022, encodeId=4385220802237, content=二审后made decision 已经两周了有这个情况的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d548736549, createdName=ms4000000513308957, createdTime=Mon Jun 03 10:20:30 CST 2024, time=2024-06-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2232987, encodeId=45d3223298e3b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学 经验分享：3月底投稿 4月26修回意见，期间状态一直是under consideration， 5.29上传修回稿 8.14接受。 总的来说还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822126, createdTime=Thu Oct 24 23:44:21 CST 2024, time=2024-10-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2227972, encodeId=34ed222e972bd, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌;增殖 经验分享：2nd 08 Submission 2nd 08 Under Consideration 24th 09 Decision Made 26th 09 收到邮件【I regret that I am unable to accept the manuscript for publication】 审稿人1：This paper does not provide any new insight. 审稿人2：I find this study suitable for publication. 综上所述，耗时近2个月，最终被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoFGKyniaLjSy7KwQPyDticyTh8W1P6Ptj682WnB3goasd1PiaaBDpLrRgCSP813Vug94Q5Ge9PNHZsw/132, createdBy=dafd2460608, createdName=xie17, createdTime=Fri Sep 27 11:02:36 CST 2024, time=2024-09-27, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海)]

2024-12-19 ms1000001793243476 来自浙江省

一审128天了，这正常吗

9 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247139, encodeId=be09224e13960, content=2024.8.14 submission 2024.8.14-8.26 editor assignment 2024.8.27 with editor 2024.9.26 接到一审回来的邮件（两个审稿人，给了两个月的时间返修） 2024.11.13 返修回去（一直是under consideration,有zip文件） 2024.12.3 dicision made 2024.12.6 小修邮件 2024.12.7 返修回去 2024.12.9 dicision made 2024.12.17 Accept in Priciple 然后提交了一个最终版本，到现在还没消息，一直是under consideration;已经20天了，有没有大神能告诉我多久能收到Proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8215640014, createdName=ms1000002147178519, createdTime=Wed Jan 08 16:00:35 CST 2025, time=2025-01-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2227948, encodeId=f420222e94880, content=偏重的研究方向：肿瘤;机制研究 经验分享：速度蛮快从大cdd转来第1天分配编辑当天即送审两周后审完给修花一个月补了实验修回修回第二天decision made 一周后原则性接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf531737941, createdName=yuig, createdTime=Fri Sep 27 08:10:40 CST 2024, time=2024-09-27, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2243526, encodeId=baaa2243526b2, content=一审128天了，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d976564110, createdName=ms1000001793243476, createdTime=Thu Dec 19 13:40:02 CST 2024, time=2024-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2233713, encodeId=68222233e13ab, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：大家好，想请问下大家，review square在哪可以看呀，目前一审修回后一周，想看一下二审是否有审稿人接受审稿。另外想请问大佬们，一审修回的几个图有点问题（不影响结果），后续可以更换图吗？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86504809827, createdName=473565137, createdTime=Mon Oct 28 17:10:32 CST 2024, time=2024-10-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2208022, encodeId=4385220802237, content=二审后made decision 已经两周了有这个情况的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d548736549, createdName=ms4000000513308957, createdTime=Mon Jun 03 10:20:30 CST 2024, time=2024-06-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2232987, encodeId=45d3223298e3b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学 经验分享：3月底投稿 4月26修回意见，期间状态一直是under consideration， 5.29上传修回稿 8.14接受。 总的来说还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822126, createdTime=Thu Oct 24 23:44:21 CST 2024, time=2024-10-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2227972, encodeId=34ed222e972bd, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌;增殖 经验分享：2nd 08 Submission 2nd 08 Under Consideration 24th 09 Decision Made 26th 09 收到邮件【I regret that I am unable to accept the manuscript for publication】 审稿人1：This paper does not provide any new insight. 审稿人2：I find this study suitable for publication. 综上所述，耗时近2个月，最终被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoFGKyniaLjSy7KwQPyDticyTh8W1P6Ptj682WnB3goasd1PiaaBDpLrRgCSP813Vug94Q5Ge9PNHZsw/132, createdBy=dafd2460608, createdName=xie17, createdTime=Fri Sep 27 11:02:36 CST 2024, time=2024-09-27, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海)]

2024-10-28 473565137 来自山东省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：大家好，想请问下大家，review square在哪可以看呀，目前一审修回后一周，想看一下二审是否有审稿人接受审稿。另外想请问大佬们，一审修回的几个图有点问题（不影响结果），后续可以更换图吗？谢谢

65 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247139, encodeId=be09224e13960, content=2024.8.14 submission 2024.8.14-8.26 editor assignment 2024.8.27 with editor 2024.9.26 接到一审回来的邮件（两个审稿人，给了两个月的时间返修） 2024.11.13 返修回去（一直是under consideration,有zip文件） 2024.12.3 dicision made 2024.12.6 小修邮件 2024.12.7 返修回去 2024.12.9 dicision made 2024.12.17 Accept in Priciple 然后提交了一个最终版本，到现在还没消息，一直是under consideration;已经20天了，有没有大神能告诉我多久能收到Proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8215640014, createdName=ms1000002147178519, createdTime=Wed Jan 08 16:00:35 CST 2025, time=2025-01-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2227948, encodeId=f420222e94880, content=偏重的研究方向：肿瘤;机制研究 经验分享：速度蛮快从大cdd转来第1天分配编辑当天即送审两周后审完给修花一个月补了实验修回修回第二天decision made 一周后原则性接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf531737941, createdName=yuig, createdTime=Fri Sep 27 08:10:40 CST 2024, time=2024-09-27, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2243526, encodeId=baaa2243526b2, content=一审128天了，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d976564110, createdName=ms1000001793243476, createdTime=Thu Dec 19 13:40:02 CST 2024, time=2024-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2233713, encodeId=68222233e13ab, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：大家好，想请问下大家，review square在哪可以看呀，目前一审修回后一周，想看一下二审是否有审稿人接受审稿。另外想请问大佬们，一审修回的几个图有点问题（不影响结果），后续可以更换图吗？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86504809827, createdName=473565137, createdTime=Mon Oct 28 17:10:32 CST 2024, time=2024-10-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2208022, encodeId=4385220802237, content=二审后made decision 已经两周了有这个情况的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d548736549, createdName=ms4000000513308957, createdTime=Mon Jun 03 10:20:30 CST 2024, time=2024-06-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2232987, encodeId=45d3223298e3b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学 经验分享：3月底投稿 4月26修回意见，期间状态一直是under consideration， 5.29上传修回稿 8.14接受。 总的来说还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822126, createdTime=Thu Oct 24 23:44:21 CST 2024, time=2024-10-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2227972, encodeId=34ed222e972bd, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌;增殖 经验分享：2nd 08 Submission 2nd 08 Under Consideration 24th 09 Decision Made 26th 09 收到邮件【I regret that I am unable to accept the manuscript for publication】 审稿人1：This paper does not provide any new insight. 审稿人2：I find this study suitable for publication. 综上所述，耗时近2个月，最终被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoFGKyniaLjSy7KwQPyDticyTh8W1P6Ptj682WnB3goasd1PiaaBDpLrRgCSP813Vug94Q5Ge9PNHZsw/132, createdBy=dafd2460608, createdName=xie17, createdTime=Fri Sep 27 11:02:36 CST 2024, time=2024-09-27, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海)]

2024-06-03 ms4000000513308957 来自天津

二审后made decision 已经两周了有这个情况的吗

0 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247139, encodeId=be09224e13960, content=2024.8.14 submission 2024.8.14-8.26 editor assignment 2024.8.27 with editor 2024.9.26 接到一审回来的邮件（两个审稿人，给了两个月的时间返修） 2024.11.13 返修回去（一直是under consideration,有zip文件） 2024.12.3 dicision made 2024.12.6 小修邮件 2024.12.7 返修回去 2024.12.9 dicision made 2024.12.17 Accept in Priciple 然后提交了一个最终版本，到现在还没消息，一直是under consideration;已经20天了，有没有大神能告诉我多久能收到Proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8215640014, createdName=ms1000002147178519, createdTime=Wed Jan 08 16:00:35 CST 2025, time=2025-01-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2227948, encodeId=f420222e94880, content=偏重的研究方向：肿瘤;机制研究 经验分享：速度蛮快从大cdd转来第1天分配编辑当天即送审两周后审完给修花一个月补了实验修回修回第二天decision made 一周后原则性接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf531737941, createdName=yuig, createdTime=Fri Sep 27 08:10:40 CST 2024, time=2024-09-27, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2243526, encodeId=baaa2243526b2, content=一审128天了，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d976564110, createdName=ms1000001793243476, createdTime=Thu Dec 19 13:40:02 CST 2024, time=2024-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2233713, encodeId=68222233e13ab, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：大家好，想请问下大家，review square在哪可以看呀，目前一审修回后一周，想看一下二审是否有审稿人接受审稿。另外想请问大佬们，一审修回的几个图有点问题（不影响结果），后续可以更换图吗？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86504809827, createdName=473565137, createdTime=Mon Oct 28 17:10:32 CST 2024, time=2024-10-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2208022, encodeId=4385220802237, content=二审后made decision 已经两周了有这个情况的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d548736549, createdName=ms4000000513308957, createdTime=Mon Jun 03 10:20:30 CST 2024, time=2024-06-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2232987, encodeId=45d3223298e3b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学 经验分享：3月底投稿 4月26修回意见，期间状态一直是under consideration， 5.29上传修回稿 8.14接受。 总的来说还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822126, createdTime=Thu Oct 24 23:44:21 CST 2024, time=2024-10-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2227972, encodeId=34ed222e972bd, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌;增殖 经验分享：2nd 08 Submission 2nd 08 Under Consideration 24th 09 Decision Made 26th 09 收到邮件【I regret that I am unable to accept the manuscript for publication】 审稿人1：This paper does not provide any new insight. 审稿人2：I find this study suitable for publication. 综上所述，耗时近2个月，最终被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoFGKyniaLjSy7KwQPyDticyTh8W1P6Ptj682WnB3goasd1PiaaBDpLrRgCSP813Vug94Q5Ge9PNHZsw/132, createdBy=dafd2460608, createdName=xie17, createdTime=Fri Sep 27 11:02:36 CST 2024, time=2024-09-27, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海)]

2024-09-11 148cbeecm22暂无昵称来自摩尔多瓦

请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗

57 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247139, encodeId=be09224e13960, content=2024.8.14 submission 2024.8.14-8.26 editor assignment 2024.8.27 with editor 2024.9.26 接到一审回来的邮件（两个审稿人，给了两个月的时间返修） 2024.11.13 返修回去（一直是under consideration,有zip文件） 2024.12.3 dicision made 2024.12.6 小修邮件 2024.12.7 返修回去 2024.12.9 dicision made 2024.12.17 Accept in Priciple 然后提交了一个最终版本，到现在还没消息，一直是under consideration;已经20天了，有没有大神能告诉我多久能收到Proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8215640014, createdName=ms1000002147178519, createdTime=Wed Jan 08 16:00:35 CST 2025, time=2025-01-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2227948, encodeId=f420222e94880, content=偏重的研究方向：肿瘤;机制研究 经验分享：速度蛮快从大cdd转来第1天分配编辑当天即送审两周后审完给修花一个月补了实验修回修回第二天decision made 一周后原则性接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf531737941, createdName=yuig, createdTime=Fri Sep 27 08:10:40 CST 2024, time=2024-09-27, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2243526, encodeId=baaa2243526b2, content=一审128天了，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d976564110, createdName=ms1000001793243476, createdTime=Thu Dec 19 13:40:02 CST 2024, time=2024-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2233713, encodeId=68222233e13ab, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：大家好，想请问下大家，review square在哪可以看呀，目前一审修回后一周，想看一下二审是否有审稿人接受审稿。另外想请问大佬们，一审修回的几个图有点问题（不影响结果），后续可以更换图吗？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86504809827, createdName=473565137, createdTime=Mon Oct 28 17:10:32 CST 2024, time=2024-10-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2208022, encodeId=4385220802237, content=二审后made decision 已经两周了有这个情况的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d548736549, createdName=ms4000000513308957, createdTime=Mon Jun 03 10:20:30 CST 2024, time=2024-06-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2232987, encodeId=45d3223298e3b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学 经验分享：3月底投稿 4月26修回意见，期间状态一直是under consideration， 5.29上传修回稿 8.14接受。 总的来说还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822126, createdTime=Thu Oct 24 23:44:21 CST 2024, time=2024-10-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2227972, encodeId=34ed222e972bd, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌;增殖 经验分享：2nd 08 Submission 2nd 08 Under Consideration 24th 09 Decision Made 26th 09 收到邮件【I regret that I am unable to accept the manuscript for publication】 审稿人1：This paper does not provide any new insight. 审稿人2：I find this study suitable for publication. 综上所述，耗时近2个月，最终被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoFGKyniaLjSy7KwQPyDticyTh8W1P6Ptj682WnB3goasd1PiaaBDpLrRgCSP813Vug94Q5Ge9PNHZsw/132, createdBy=dafd2460608, createdName=xie17, createdTime=Fri Sep 27 11:02:36 CST 2024, time=2024-09-27, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海)]

2024-10-24 ms1000001788822126 来自北京

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤学
经验分享：3月底投稿
4月26修回意见，期间状态一直是under consideration，
5.29上传修回稿
8.14接受。
总的来说还可以。

60 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247139, encodeId=be09224e13960, content=2024.8.14 submission 2024.8.14-8.26 editor assignment 2024.8.27 with editor 2024.9.26 接到一审回来的邮件（两个审稿人，给了两个月的时间返修） 2024.11.13 返修回去（一直是under consideration,有zip文件） 2024.12.3 dicision made 2024.12.6 小修邮件 2024.12.7 返修回去 2024.12.9 dicision made 2024.12.17 Accept in Priciple 然后提交了一个最终版本，到现在还没消息，一直是under consideration;已经20天了，有没有大神能告诉我多久能收到Proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8215640014, createdName=ms1000002147178519, createdTime=Wed Jan 08 16:00:35 CST 2025, time=2025-01-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2227948, encodeId=f420222e94880, content=偏重的研究方向：肿瘤;机制研究 经验分享：速度蛮快从大cdd转来第1天分配编辑当天即送审两周后审完给修花一个月补了实验修回修回第二天decision made 一周后原则性接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf531737941, createdName=yuig, createdTime=Fri Sep 27 08:10:40 CST 2024, time=2024-09-27, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2243526, encodeId=baaa2243526b2, content=一审128天了，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d976564110, createdName=ms1000001793243476, createdTime=Thu Dec 19 13:40:02 CST 2024, time=2024-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2233713, encodeId=68222233e13ab, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：大家好，想请问下大家，review square在哪可以看呀，目前一审修回后一周，想看一下二审是否有审稿人接受审稿。另外想请问大佬们，一审修回的几个图有点问题（不影响结果），后续可以更换图吗？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86504809827, createdName=473565137, createdTime=Mon Oct 28 17:10:32 CST 2024, time=2024-10-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2208022, encodeId=4385220802237, content=二审后made decision 已经两周了有这个情况的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d548736549, createdName=ms4000000513308957, createdTime=Mon Jun 03 10:20:30 CST 2024, time=2024-06-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2232987, encodeId=45d3223298e3b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学 经验分享：3月底投稿 4月26修回意见，期间状态一直是under consideration， 5.29上传修回稿 8.14接受。 总的来说还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822126, createdTime=Thu Oct 24 23:44:21 CST 2024, time=2024-10-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2227972, encodeId=34ed222e972bd, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌;增殖 经验分享：2nd 08 Submission 2nd 08 Under Consideration 24th 09 Decision Made 26th 09 收到邮件【I regret that I am unable to accept the manuscript for publication】 审稿人1：This paper does not provide any new insight. 审稿人2：I find this study suitable for publication. 综上所述，耗时近2个月，最终被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoFGKyniaLjSy7KwQPyDticyTh8W1P6Ptj682WnB3goasd1PiaaBDpLrRgCSP813Vug94Q5Ge9PNHZsw/132, createdBy=dafd2460608, createdName=xie17, createdTime=Fri Sep 27 11:02:36 CST 2024, time=2024-09-27, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海)]

2024-09-27 xie17 来自辽宁省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：乳腺癌;增殖
经验分享：2nd 08 Submission
2nd 08 Under Consideration
24th 09 Decision Made
26th 09 收到邮件【I regret that I am unable to accept the manuscript for publication】

审稿人1：This paper does not provide any new insight.
审稿人2：I find this study suitable for publication.

综上所述，耗时近2个月，最终被拒。

34 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2247139, encodeId=be09224e13960, content=2024.8.14 submission 2024.8.14-8.26 editor assignment 2024.8.27 with editor 2024.9.26 接到一审回来的邮件（两个审稿人，给了两个月的时间返修） 2024.11.13 返修回去（一直是under consideration,有zip文件） 2024.12.3 dicision made 2024.12.6 小修邮件 2024.12.7 返修回去 2024.12.9 dicision made 2024.12.17 Accept in Priciple 然后提交了一个最终版本，到现在还没消息，一直是under consideration;已经20天了，有没有大神能告诉我多久能收到Proof呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8215640014, createdName=ms1000002147178519, createdTime=Wed Jan 08 16:00:35 CST 2025, time=2025-01-08, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2215807, encodeId=fb06221580eda, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肺癌;肿瘤生物学 经验分享：今天刚刚接收一篇，分享一下投稿经历： 第一阶段： Submission ---- 25th Jan 24 Under Consideration ---- 26th Jan 24 Decision Made ---- 9th Apr 24 收到一审意见 ---- 15th Apr 24 第二阶段： Submission ---- 20th Jun 24 Under Consideration ---- 20th Jun 24 Decision Made ---- 15th Jul 24 Accepted in Principle ---- 19th Jul 24, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=628, replyNumber=35, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Fri Jul 19 23:57:59 CST 2024, time=2024-07-19, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2227948, encodeId=f420222e94880, content=偏重的研究方向：肿瘤;机制研究 经验分享：速度蛮快从大cdd转来第1天分配编辑当天即送审两周后审完给修花一个月补了实验修回修回第二天decision made 一周后原则性接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf531737941, createdName=yuig, createdTime=Fri Sep 27 08:10:40 CST 2024, time=2024-09-27, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2243526, encodeId=baaa2243526b2, content=一审128天了，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d976564110, createdName=ms1000001793243476, createdTime=Thu Dec 19 13:40:02 CST 2024, time=2024-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2233713, encodeId=68222233e13ab, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：大家好，想请问下大家，review square在哪可以看呀，目前一审修回后一周，想看一下二审是否有审稿人接受审稿。另外想请问大佬们，一审修回的几个图有点问题（不影响结果），后续可以更换图吗？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86504809827, createdName=473565137, createdTime=Mon Oct 28 17:10:32 CST 2024, time=2024-10-28, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2208022, encodeId=4385220802237, content=二审后made decision 已经两周了有这个情况的吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d548736549, createdName=ms4000000513308957, createdTime=Mon Jun 03 10:20:30 CST 2024, time=2024-06-03, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2225265, encodeId=57d52225265e8, content=请问一审修回去，修回去第二天状态就变成decision made了，这是拒稿了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8f25330837, createdName=148cbeecm22暂无昵称, createdTime=Wed Sep 11 21:49:37 CST 2024, time=2024-09-11, status=1, ipAttribution=摩尔多瓦), GetPortalCommentsPageByObjectIdResponse(id=2232987, encodeId=45d3223298e3b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤学 经验分享：3月底投稿 4月26修回意见，期间状态一直是under consideration， 5.29上传修回稿 8.14接受。 总的来说还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822126, createdTime=Thu Oct 24 23:44:21 CST 2024, time=2024-10-24, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2227972, encodeId=34ed222e972bd, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌;增殖 经验分享：2nd 08 Submission 2nd 08 Under Consideration 24th 09 Decision Made 26th 09 收到邮件【I regret that I am unable to accept the manuscript for publication】 审稿人1：This paper does not provide any new insight. 审稿人2：I find this study suitable for publication. 综上所述，耗时近2个月，最终被拒。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoFGKyniaLjSy7KwQPyDticyTh8W1P6Ptj682WnB3goasd1PiaaBDpLrRgCSP813Vug94Q5Ge9PNHZsw/132, createdBy=dafd2460608, createdName=xie17, createdTime=Fri Sep 27 11:02:36 CST 2024, time=2024-09-27, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2226688, encodeId=159b22266888d, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：24年3.26投稿 4.28修回意见，在这期间状态一直是under consideration 5.22上传修回稿，后面编辑让从新提交了几次 8月20接受。 整体感觉还可以，很庆幸。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788820006, createdTime=Thu Sep 19 23:16:11 CST 2024, time=2024-09-19, status=1, ipAttribution=上海)]

2024-09-19 ms1000001788820006 来自上海

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：24年3.26投稿
4.28修回意见，在这期间状态一直是under consideration
5.22上传修回稿，后面编辑让从新提交了几次
8月20接受。
整体感觉还可以，很庆幸。

73 12

展开12条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务